Introduction
============

Diabetes mellitus (DM) is a serious global health problem and there is clear evidence of the negative influence of diabetes on the prevalence, severity, and prognosis of cardiovascular disease ([@b1-mmr-16-04-3720]). Disorders of the vasculature, particularly coronary artery disease and hypertension, increase the incidence of mortality in individuals with DM ([@b2-mmr-16-04-3720]). Diabetic patients are at greater risk of developing heart problems that are independent of vascular dysfunction which is indicative of a distinct diabetic cardiomyopathy ([@b3-mmr-16-04-3720],[@b4-mmr-16-04-3720]). Impaired contractile function including a reduction in amplitude and depressed time course of contraction and relaxation of ventricular myocytes have been demonstrated in experimental models of DM including the streptozotocin (STZ)-induced diabetic rat ([@b5-mmr-16-04-3720]--[@b10-mmr-16-04-3720]). These changes in contractility have been partly attributed to alterations in Ca^2+^ transport including elevated diastolic Ca^2+^ and depression in amplitude and prolonged time course of the intracellular Ca^2+^ transient ([@b6-mmr-16-04-3720]--[@b8-mmr-16-04-3720],[@b11-mmr-16-04-3720],[@b12-mmr-16-04-3720]). Mechanisms underlying the alterations in Ca^2+^ transient include impaired sarcoplasmic reticulum (SR) Ca^2+^ transport and suppressed L-type Ca^2+^ current and Na^+^/Ca^2+^ exchange current ([@b5-mmr-16-04-3720]--[@b7-mmr-16-04-3720],[@b11-mmr-16-04-3720]--[@b15-mmr-16-04-3720]). DM also has profound effects on the electrical conduction system of the heart which may give rise to arhythmogenic activity. Prolongation of the QT interval and QRS complex correlate with an increased incidence of sudden cardiac death in diabetic patients ([@b16-mmr-16-04-3720],[@b17-mmr-16-04-3720]). Atrial fibrillation is prevalent and there is a higher incidence of atrioventricular block in diabetic patients compared to healthy controls ([@b17-mmr-16-04-3720]--[@b20-mmr-16-04-3720]).

Previous *in vivo* biotelemetry and isolated perfused heart studies have demonstrated reduced heart rate in the STZ rat ([@b21-mmr-16-04-3720]--[@b23-mmr-16-04-3720]). Slowing of electrical conduction has also been demonstrated in diabetic rat myocardium ([@b24-mmr-16-04-3720]). Various experimental studies in animal models of DM have variously demonstrated changes in ion channel activity including depressed L-type calcium current, transient outward potassium current, rapid and slow delayed potassium rectifier currents all of which can result in a prolongation of action potential duration and reduced heart rate ([@b23-mmr-16-04-3720],[@b25-mmr-16-04-3720]--[@b33-mmr-16-04-3720]). DM can increase the duration of the sinoatrial node (SAN) action potential and prolong sino-atrial node conduction time and pacemaker cycle length which is associated with alterations in intercellular gap junctional coupling ([@b23-mmr-16-04-3720],[@b34-mmr-16-04-3720]). Previous studies in STZ rat have demonstrated a variety of changes in mRNA, and in some cases proteins, that are important to the generation of action potentials in the SAN ([@b35-mmr-16-04-3720]). Increased duration of the action potential in STZ-induced diabetic rat AVN has been attributed to a leftward shift in the zero current potential under voltage clamp, a reduction in peak L-type Ca^2+^ current density and reduced amplitude of delayed rectifier and hyperpolarization-activated currents ([@b32-mmr-16-04-3720]). L-type calcium channels are fundamental to normal activity in the atrioventricular node (AVN) region and L-type calcium current contributes to the late stages of the pacemaker potential and generation of the action potential upstroke, and is responsible for the timing of conduction velocity through the AVN, thereby contributing to PR interval duration.

Previous studies have demonstrated increased action potential duration associated with a reduced action potential firing rate that is associated with reductions in L-type calcium current, delayed rectifier and hyperpolarization-activated currents in AVN cells from STZ-induced diabetic rat ([@b32-mmr-16-04-3720],[@b33-mmr-16-04-3720]). Modification of ion channel properties either by altered trafficking and expression, or post-translational modification of channel gating properties, can therefore have a significant impact on AVN function, and result in clinical AVN abnormalities. To further clarify the molecular basis of electrical disturbances in the AVN of diabetic heart the profile of mRNA that encodes a wide variety of proteins that are associated with the generation and conduction of electrical activity in the AVN has been evaluated in the STZ-induced diabetic rat heart.

Materials and methods
=====================

### Experimental protocol

Forty male Wistar rats aged 8 weeks were divided into 2 subgroups. All animals received normal rat chow and drinking water *ad libitum*. One subgroup of rats received STZ/citrate buffer (60 mg/kg, intraperitoneal) whilst the other subgroup received citrate buffer alone. Blood glucose was measured 5 days following STZ treatment to confirm diabetes. Experiments began 12 weeks after STZ treatment. Body weight, heart weight and blood glucose were measured immediately prior to experiments. Approval for this study was obtained from the Animal Ethics Committee, College of Medicine and Health Sciences, United Arab Emirates University.

### Expression of mRNA

Expression of genes encoding a wide range of cardiac proteins was assessed using previously described techniques with small modifications ([@b35-mmr-16-04-3720]). After animals were sacrificed the hearts were removed rapidly and placed in a dish containing: NaCl 140 mM; KCl 5.4 mM; MgCl~2~ 1 mM; HEPES 5 mM; D-glucose 5.5 mM; CaCl~2~ 1.8 mM and adjusted to pH 7.4 with NaOH. Hearts were dissected and 2 mm biopsy samples of AVN were carefully collected from 20 STZ and 20 control hearts as illustrated in [Fig. 1](#f1-mmr-16-04-3720){ref-type="fig"} and according to previously described techniques ([@b36-mmr-16-04-3720]--[@b38-mmr-16-04-3720]). Immediately after removal AVN samples were immersed in RNAlater (AM7021; Life Technologies, Carlsbad, CA, USA) and stored overnight at room temperature to allow thorough penetration of the tissue. AVN samples were then frozen at −20°C pending further processing. Samples were homogenized at 6,500 rpm for 2 runs of 20 sec each with a 15 sec gap (Preceylls 24; Bertin Technologies, Raleigh, NC, USA). The SV Total RNA Isolation system (Promega, Madison, WI, USA) was used to isolate total RNA. The concentration and purity of the RNA was determined by measuring the ratio of absorbance at 260 nm and 280 nm (ND-1000; NanoDrop). A two-step RT-PCR procedure was used to generate cDNA. Total RNA (500 ng) was converted into cDNA in a 25 µl PCR reaction with 10x RT Buffer 2.0 µl, 25x dNTP Mix (100 mM) 0.8 µl, 10x RT Random Primers 2.0 µl, MultiScribe™ Reverse Transcriptase 1.0 µl, RNase inhibitor 1.0 µl, and nuclease-free H~2~O (High Capacity cDNA Reverse Transcription kit (4374966; Applied Biosystems, Foster, CA, USA). Reverse transcription was carried out using the following protocol: 25°C for 10 min, 37°C for 120 min, and 85°C for 5 min on the Veriti thermal cycler (Applied Biosystems). Gene Expression Assays were performed using custom TaqMan Low Density Arrays (Format 32, 4346799; Applied Biosystems). The TaqMan assays are pre-loaded in each reaction well of the array in triplicate for each RNA sample. As in previous experiments in heart 18S RNA was used as an endogenous control ([@b39-mmr-16-04-3720],[@b40-mmr-16-04-3720]). Expression of 18S was not significantly different (P\>0.05) between AVN samples collected from STZ and control hearts. cDNA (RNA-equivalent) (100 ng) was loaded together with 2x TaqMan Gene Expression Master Mix (No AmpErase UNG; Applied Biosystems) for a total of 100 µl per port. Two AVN samples were combined for each real-time RT-PCR assay. Real-time RT-PCR was performed in a Fast ABI Prism 7900HT Sequence Detection system (Applied Biosystems). The PCR thermal cycling parameters were run in standard mode as follows: 50°C for 2 min, 94.5°C for 10 min, followed by 40 cycles of 97°C for 30 sec and 59.7°C for 1 min. Results were initially analyzed using ABI Prism 7900HT SDS, v2.4. Calculations and statistical analysis were performed by the SDS RQ Manager 1.1.4 software using the 2^−ΔΔCt^ method with a relative quantification RQmin/RQmax confidence set at 95%. A list of the target genes, proteins and protein descriptions are shown in [Table I](#tI-mmr-16-04-3720){ref-type="table"}.

### Expression of protein

Protein expression was measured using previously described SDS-PAGE and western blotting techniques with small modifications ([@b35-mmr-16-04-3720]). AVN from STZ and control rats were carefully dissected, rinsed with ice-cold saline and homogenised in RIPA buffer (Tris 50 mM; NaCl 150 mM; Triton X 1%; sodium deoxylate 0.5%; SDS 0.1% adjusted to pH 7.4 and finally addition of PMSF 0.1 mM-Sigma, P7626) at 6,500 rpm for 2 runs of 20 sec each with a 15 sec gap (Preceylls 24; Bertin Technologies). Protein concentration was measured with Bio-Rad reagent. The supernatant was used for SDS-PAGE and western blotting. Protein (40 µg) was electrophoretically separated onto 8 or 10% (depending on the molecular weight of the protein to be separated) polyacrylamide gels and transferred onto nitrocellulose membranes. Expression of the specific proteins was confirmed by immunoreaction with their specific antibodies by western blot analysis. β-actin was used as a loading control. Blots were developed using the Pierce Western Blot kit. Images were obtained using the Typhoon FLA 9500, GE Healthcare Bio-Sciences AB (Uppsala, Sweden). Quantitation of protein was performed using the method described in the following website: <http://lukemiller.org/index.php/2010/11/analyzing-gels-and-western-blots-with-image-j/>.

For each lane the protein level was normalized to that of β-actin. The ratio of specific protein signal to that of the β-actin control was used to calculate fold-change.

### Statistical analysis

Results were expressed as the mean ± SEM. of 'n' observations. Statistical comparisons were performed using independent sample t-test (SPSS vs. 20). P≤0.05 was considered to indicate a statistically significant difference.

Results
=======

General characteristics: Bodyweight and heart weight were reduced and heart weight/bodyweight ratio was increased in STZ rats compared to controls. Blood glucose was elevated 5-fold in STZ rats compared to controls ([Table II](#tII-mmr-16-04-3720){ref-type="table"}).

### Expression of mRNA

Expression of genes encoding intercellular proteins is shown in [Fig. 2](#f2-mmr-16-04-3720){ref-type="fig"}. There were no significant (P\>0.05) differences in the expression of mRNA in AVN from STZ compared to control heart. Expression of genes encoding various cell membrane transport and intracellular Ca^2+^ transport and regulatory proteins are shown in [Figs. 3](#f3-mmr-16-04-3720){ref-type="fig"} and [4](#f4-mmr-16-04-3720){ref-type="fig"}, respectively. mRNA for *Atp1b1* (2-fold), *Atp2b1* (2-fold), *Slc8a1* (6-fold), *Trpc1* (7-fold), *Trpc3* (2-fold), *Casq2* (2-fold), *Ryr2* (3-fold), *Ryr3* (4-fold) were all significantly (P\<0.05) upregulated in AVN from STZ compared to control heart. Expression of genes encoding the hyperpolarization-activated cyclic nucleotide-gated channel proteins are shown in [Fig. 5](#f5-mmr-16-04-3720){ref-type="fig"}. mRNA for *Hcn2* (2-fold) and *Hcn3* (9-fold) were significantly upregulated in AVN from STZ compared to control heart. Expression of genes encoding calcium channel proteins are shown in [Fig. 6](#f6-mmr-16-04-3720){ref-type="fig"}. mRNA for *Cacnb2* (2-fold) was upregulated in AVN from STZ compared to control heart. Expression of genes encoding sodium channel proteins are shown in [Fig. 7](#f7-mmr-16-04-3720){ref-type="fig"}. mRNA for *Scn3a (3-fold)*, *Scn4a* (3-fold), *Scn7a* (2-fold) and *Scn3b* (7-fold) were upregulated in AVN from STZ compared to control heart. Expression of genes encoding potassium channel proteins are shown in [Fig. 8](#f8-mmr-16-04-3720){ref-type="fig"}. mRNA for *Kcna4* (3-fold), *Kcnh2* (4-fold), *Kcnn2* (9-fold), Kcnj3 (2-fold), Kcnj5 (5-fold), *Kcnj11* (2-fold), *Kcnk1* (2-fold), *Kcnk2* (2-fold) and *Kcnk3* (3-fold) were upregulated in AVN from STZ compared to control heart. Expression of genes encoding various miscellaneous proteins are shown in [Fig. 9](#f9-mmr-16-04-3720){ref-type="fig"}. mRNA for *Abcc9* (2-fold), *Nppb (3-fold)* and *Pias3* (8-fold) were upregulated in AVN from STZ compared to Control heart.

### Expression of proteins

Representative Western blots comparing various proteins from STZ and control AVN are shown in [Fig. 10A](#f10-mmr-16-04-3720){ref-type="fig"}. The protein/actin ratio for the different proteins are shown in [Fig. 10B](#f10-mmr-16-04-3720){ref-type="fig"}. Expression of K~ir~3.4, NCX1 and BNP were significantly upregulated and SK2, ERG-1, HCN3 and Na~v~β3 were not significantly altered in AVN from STZ compared to control heart.

Discussion
==========

Diabetes in the STZ-induced diabetic rat was characterized by reduced bodyweight and heart weight and increased heart weight/bodyweight ratio and a 5-fold increase in blood glucose. Major findings of this study included: i) upregulation of *Slc8a1* mRNA and NCX1 protein; ii) upregulation of *Trpc1* and *Trpc3* mRNA; iii) upregulation of *Ryr2* and *Ryr3* mRNA; iv) upregulation of *Hcn2 and Hcn3*; v) upregulation of *Cacnb2* mRNA; vi) upregulation of *Scn3a/4a/7a* and *Scn3b*; vii) upregulation of *Kcna4, Kcnh2, Kcnn2, Kcnj3/11* and *Kcnk2/3* mRNA and *Kcnj5* mRNA and Ki~r~3.4 protein; and viii) upregulation of *Nppb* mRNA and BNP protein in AVN from STZ compared to control heart.

*Slc8a1* mRNA and NCX1 protein were upregulated in AVN from STZ rat heart. Upregulation of *Slc8a1* has also recently been reported in the SAN from STZ-induced diabetic rat ([@b35-mmr-16-04-3720]). The *Slc8* gene family encodes the Na^+^/Ca^2+^ exchanger (NCX). Altered expression and regulation of NCX proteins contribute to abnormal Ca^2+^ homeostasis in heart failure, arrhythmia, hypertension and diabetes ([@b41-mmr-16-04-3720]). Impaired Ca^2+^ homeostasis, due to depressed SR Ca^2+^ ATPase and NCX activity and NCX current have been demonstrated in ventricular myocytes from STZ-induced diabetic heart ([@b6-mmr-16-04-3720],[@b42-mmr-16-04-3720],[@b43-mmr-16-04-3720]). The functional importance of NCX current in rabbit and mouse AVN cells has been demonstrated and depressed L-type Ca^2+^ current has been reported in AVN cells from STZ rat heart ([@b32-mmr-16-04-3720],[@b33-mmr-16-04-3720],[@b44-mmr-16-04-3720]--[@b46-mmr-16-04-3720]). Upregulation of *Slc8a1* mRNA and NCX1 protein in the AVN from STZ heart may provide a compensatory pathway to facilitate Ca^2+^ influx and/or Ca^2+^ efflux from the cell which may be required for the generation and recovery of action potentials in AVN cells.

*Trpc1* and *Trpc3* were upregulated in AVN from STZ rat heart. Upregulation of *Trpc1* has also recently been reported in the SAN from STZ-induced diabetic rat ([@b35-mmr-16-04-3720]). The transient receptor potential channels (TRPCs) are a large family of non-selective and non-voltage-gated ion channels that convey signaling information linked to a broad range of sensory inputs including neurohormonal and mechanical load stimulation ([@b47-mmr-16-04-3720]). TRPC1 is a mechano-sensitive, non-selective cation channel which is expressed in ventricle and atrium in a variety of mammalian species including rat ([@b48-mmr-16-04-3720]--[@b50-mmr-16-04-3720]). TRPC1 functions in Ca^2+^ influx, and its upregulation is involved in the development of cardiac hypertrophy ([@b51-mmr-16-04-3720]). TRPC1 is also expressed in mouse SAN and in single pacemaker cells and mouse SAN may exhibit store-operated Ca^2+^ channel (SOCC) activity which may suggest that SOCCs are involved in regulating pacemaker firing rate ([@b52-mmr-16-04-3720]). Upregulation of *Trpc1* may be a consequence of hemodynamic disturbances in the diabetic heart which in turn stimulates mechano-sensitive TRPC channels thereby providing an alternative entry pathway for Ca^2+^ in the face of depressed L-type Ca^2+^ current in AVN cells and reduced heart rate in STZ-induced diabetic heart ([@b32-mmr-16-04-3720],[@b33-mmr-16-04-3720]). Previous studies have reported elevation of mean arterial pressure in STZ-induced diabetic rats which may in turn lead to hypertrophy of the heart which would be consistent with the increase in heart weight to body weight ratio, which in turn might elicit an effect on the mechano-sensitive channels ([@b53-mmr-16-04-3720]).

*Ryr2* and *Ryr3* were upregulated in AVN from STZ rat heart. The *Ryr* family of genes encode proteins that form the SR Ca^2+^ release channel. SR Ca^2+^ cycling is important for the genesis of spontaneous activity in the AVN ([@b44-mmr-16-04-3720],[@b54-mmr-16-04-3720]--[@b56-mmr-16-04-3720]). Whilst little is known about the effects of diabetes on SR Ca^2+^ signaling in the AVN, previous studies have demonstrated depressed SR Ca^2+^ loading, Ca^2+^ uptake/release and Ca^2+^ leak in ventricular myocytes from STZ-induced diabetic heart ([@b6-mmr-16-04-3720],[@b12-mmr-16-04-3720],[@b15-mmr-16-04-3720],[@b57-mmr-16-04-3720]). These disturbances in SR Ca^2+^ signaling have been variously attributed to structural and/or functional defects of the RYR2 receptors or Ca^2+^-ATPase (SERCA) pump proteins ([@b12-mmr-16-04-3720],[@b15-mmr-16-04-3720],[@b58-mmr-16-04-3720]--[@b61-mmr-16-04-3720]). It was also interesting to note upregulation of *Casq2*, an SR Ca^2+^ binding protein, in AVN from STZ rat. Upregulation of *Ryr2* may facilitate release of Ca^2+^ from the SR which in turn might compensate for depressed L-type Ca^2+^ current in AVN from STZ compared to control heart ([@b32-mmr-16-04-3720],[@b33-mmr-16-04-3720]).

*Hcn2* and *Hcn3* were upregulated in AVN from STZ rat heart. Upregulation of *Hcn3* was only associated with a small increase in HCN3 protein in AVN from STZ compared to control heart. The funny current which is conducted through the hyperpolarization-activated cyclic nucleotide channels plays a key role in the generation of the pacemaker current and hence, rhythmicity of the heart. Previous studies have demonstrated reduced action potential firing rates accompanied by a reduction in the amplitude of funny current, L-type Ca^2+^ current and delayed rectifier current in AVN cells from STZ-induced diabetic heart ([@b32-mmr-16-04-3720],[@b33-mmr-16-04-3720]). In the longer term, as DM progresses, upregulation of *Hcn2* and/or *Hcn3*, if accompanied by an increase in HCN2 and HCN3 protein, might result in an increase in the conductance of funny current and steepening of the slope of the pacemaker potential, which in turn would increase heart rate.

*Cacnb2* was upregulated in AVN from STZ rat heart. *Cacnb2* codes for the auxiliary β-subunit (Cavβ) which is an important modulator of Ca^2+^ channel activity. Expression of the β-subunit is required for normal function of cardiac L-type Ca^2+^ channels. Cavβ binds to the α1 pore-forming subunit of L-type Ca^2+^ channels and augments L-type Ca^2+^ current by facilitating channel opening and increasing the number of channels in the membrane ([@b62-mmr-16-04-3720]). Several cardiovascular diseases including hypertension, heart failure and sudden cardiac death have been linked to *Cacnb2* ([@b63-mmr-16-04-3720]). Upregulation of *Cacnb2* may facilitate L-type Ca^2+^ channel opening and provide a compensatory pathway for depressed L-type Ca^2+^ current in AVN cells from STZ compared to control heart ([@b32-mmr-16-04-3720],[@b33-mmr-16-04-3720]). Interestingly, there were no significant changes in the expression of *Cacna1c* and *Cacna1d* suggesting that at this stage of diabetes (12 weeks after STZ treatment), whilst other changes in gene expression are taking place, changes to the α-1C and α-1D are not yet evident.

*Scn3b* and *Scn4a* were upregulated in AVN from STZ rat heart. Sodium channel SCN5a (Nav1.5) is regulated by four sodium channel auxiliary β subunits (SCN1-4b). Mutations in SCN3b have been associated with ventricular and atrial arrhythmias and altered electrophysiological properties of the sodium channel including reduced peak sodium current ([@b64-mmr-16-04-3720]--[@b66-mmr-16-04-3720]). Sodium channel SCN4A (Nav1.4) encodes the α-subunit of the voltage-gated sodium channel Nav1.4 and studies suggest the involvement of SCN4A variants in the pathophysiological mechanisms underlying arrhythmias in some patients with Brugada syndrome ([@b67-mmr-16-04-3720],[@b68-mmr-16-04-3720]). The role of SCN3B and SCN4A in AVN remains to be clarified.

*Kcna4, Kcnh2, Kcnj3/5/11, Kcnk2/3 and Kcnn2* were all upregulated in AVN from STZ rat heart. Upregulation of *Kcnj5* and *Kcnk3* have also recently been reported in the SAN from STZ-induced diabetic rat ([@b35-mmr-16-04-3720]). K~ir~3.4 protein encoded by *Kcnj5* was upregulated and ERG-1 encoded by *Kcnh2* was unaltered in AVN from STZ compared to control heart. At this stage of diabetes (12 weeks after STZ treatment) alterations in gene expression might not translate into alterations in protein expression. *Kcna4* encodes the Kv1.4 protein which forms the channel that carries transient outward current which makes a major contribution to the repolarizing current and termination of the cardiac action potential. Transient outward current has been widely demonstrated in different regions of the heart including ventricular myocytes and AVN cells ([@b69-mmr-16-04-3720]--[@b71-mmr-16-04-3720]). *Kcnh2* encodes ERG-1 protein which is the α subunit of a potassium ion channel that mediates the repolarizing rapid delayed rectifier current (I~Kr~) current in the cardiac action potential. Several studies have characterized the electrophysiological properties of I~Kr~ in AVN cells from various species including rabbit and mouse ([@b54-mmr-16-04-3720],[@b71-mmr-16-04-3720]--[@b73-mmr-16-04-3720]). I~Kr~ plays a role in both action potential repolarization and pacemaker depolarization ([@b74-mmr-16-04-3720],[@b75-mmr-16-04-3720]). The *Kcnj5* gene encodes the G-protein-activated inwardly rectifying potassium channel 4 and loss of the K~ir~3.4 gene strongly reduces cholinergic regulation of pacemaker activity in SAN cells and delays recovery of heart rate after stress, physical exercise or pharmacological β-adrenergic stimulation ([@b76-mmr-16-04-3720]). Upregulation of *Kcnj5* and K~ir~3.4 protein might partly underlie the slow heart rate in STZ rat heart ([@b21-mmr-16-04-3720]--[@b23-mmr-16-04-3720]). *Kcnn2* encodes the small calcium-activated potassium channel member SK2. SK2 mRNA has been detected in a variety of organs including heart and within the heart expression of SK channels are more abundant in the atria and pacemaking tissues compared with the ventricles ([@b77-mmr-16-04-3720],[@b78-mmr-16-04-3720]). Calcium-activated potassium channels are present in a variety of cells and serve to integrate changes in intracellular Ca^2+^ with changes in K^+^ conductance and membrane potential ([@b79-mmr-16-04-3720]). Overexpression of SK2 channels result in shortening of the spontaneous action potentials of AVN cells and an increase in firing frequency whilst genetic knockout of SK2 channels result in the delay in atrial myocyte repolarization and atrial arrhythmias ([@b80-mmr-16-04-3720],[@b81-mmr-16-04-3720]). Recent studies have demonstrated down-regulation of SK2 and prolonged action potentials in STZ-induced diabetic atria ([@b82-mmr-16-04-3720]).

*Nppb* and BNP protein were upregulated in AVN from STZ rat heart. Upregulation of *Nppa* and *Nppb* have recently been reported in the SAN from STZ-induced diabetic rat ([@b35-mmr-16-04-3720]). The natriuretic peptides are a family of related peptides that include atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) that are secreted from the cardiac atria and ventricles ([@b83-mmr-16-04-3720]). ANP and BNP decrease blood pressure and cardiac hypertrophy and BNP acts locally to reduce ventricular fibrosis and they are both involved in the pathogenic mechanisms leading to major cardiovascular diseases, including heart failure, coronary heart diseases, hypertension and left ventricular hypertrophy ([@b83-mmr-16-04-3720]--[@b85-mmr-16-04-3720]). Previous studies have demonstrated increases in ANP and BNP in blood plasma and atrial tissues and varying effects of ANP and BNP on the amplitude and kinetics of shortening and intracellular Ca^2+^ in ventricular myocytes from STZ-induced diabetic rat ([@b86-mmr-16-04-3720],[@b87-mmr-16-04-3720]). BNP has been shown to increase heart rate and electrical conduction velocity in isolated hearts and in the SAN and also increase spontaneous action potential frequency in isolated SAN myocytes ([@b88-mmr-16-04-3720]). Upregulation of *Nppb* and BNP protein in the AVN may be associated with mechanisms that compensate for the low heart rate seen in the STZ-induced diabetic heart or alternatively be a consequence of the hypertrophy ([@b21-mmr-16-04-3720]--[@b23-mmr-16-04-3720],[@b86-mmr-16-04-3720],[@b87-mmr-16-04-3720]).

The SAN and AVN contribute to the generation and orderly propagation of electrical signals in the heart and it is interesting that the expression of genes that encode a variety of proteins involved in cardiac electrical transmission are similarly altered in the SAN and AVN of STZ-induced diabetic rat ([@b35-mmr-16-04-3720]). This study has demonstrated differences in the profile of mRNA encoding a variety of proteins that are associated with the generation, conduction and regulation of electrical signals in the AVN of STZ-induced diabetic rat heart. Data from this study will provide a basis for a substantial range of future studies to investigate whether changes in mRNA translate into changes in electrophysiological function.
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![Expression of genes encoding various intercellular proteins. Data are mean ± SEM, n=6--8 samples from STZ and control rat each containing samples from 2 hearts.](MMR-16-04-3720-g01){#f2-mmr-16-04-3720}

![Expression of genes encoding various cell membrane transport proteins. Data are mean ± SEM, n=5--8 samples from STZ and control rat each containing samples from 2 hearts. \*P\<0.05, \*\*P\<0.01 vs. CON-AVN.](MMR-16-04-3720-g02){#f3-mmr-16-04-3720}

![Expression of genes encoding various intracellular Ca^2+^ transport and Ca^2+^ regulation proteins. Data are mean ± SEM, n=7--8 samples from STZ and control rat each containing samples from 2 hearts. \*P\<0.05, \*\*P\<0.01 vs. CON-AVN.](MMR-16-04-3720-g03){#f4-mmr-16-04-3720}

![Expression of genes encoding various hyperpolarization-activated cyclic-nucleotide-gated channels. Data are mean ± SEM, n=5--8 samples from STZ and control rat each containing samples from 2 hearts. \*P\<0.05 vs. CON-AVN.](MMR-16-04-3720-g04){#f5-mmr-16-04-3720}

![Expression of genes encoding various calcium channel proteins. Data are mean ± SEM, n=5--9 samples from STZ and control rat each containing samples from 2 hearts. \*\*P\<0.01 vs. CON-AVN.](MMR-16-04-3720-g05){#f6-mmr-16-04-3720}

![Expression of genes encoding various sodium channel proteins. Data are mean ± SEM, n=5--9 samples from STZ and control rat each containing samples from 2 hearts. \*P\<0.05, \*\*P\<0.01 vs. CON-AVN.](MMR-16-04-3720-g06){#f7-mmr-16-04-3720}

![(A and B) Expression of genes encoding various potassium channel proteins. Data are mean ± SEM, n=5--8 samples from STZ and control rat each containing samples from 2 hearts. \*P\<0.05, \*\*P\<0.01 vs. CON-AVN.](MMR-16-04-3720-g07){#f8-mmr-16-04-3720}

![Expression of genes encoding miscellaneous cardiac proteins. Data are mean ± SEM, n=6--8 samples from STZ and control rat each containing samples from 2 hearts. \*P\<0.05, \*\*P\<0.01 vs. CON-AVN.](MMR-16-04-3720-g08){#f9-mmr-16-04-3720}

![(A) Typical western blot comparing expression of various proteins from STZ and control AVN. β-actin which was used as the loading control is also shown in each blot. The blots shown are representative of 6 individual samples from STZ and control rats. (B) Protein/β-actin ratios for the different proteins. Data are mean ± SEM, n=6 samples from STZ and control rat each containing 3 pooled AVNs from a total of 18 hearts AVN. \*P\<0.05, \*\*P\<0.01 vs. CON-AVN.](MMR-16-04-3720-g09){#f10-mmr-16-04-3720}

###### 

Target genes and proteins.

  Genes                                                          Proteins          Protein descriptions
  -------------------------------------------------------------- ----------------- -------------------------------------------------------------------------
  Intercellular proteins                                                           
    *Gja1*                                                       Cx43              Connexin43
    *Gja5*                                                       Cx40              Connexin40
    *Gjc1*                                                       Cx45              Connexin45
    *Gjd3*                                                       Cx31.9            Connexin31.9
  Cell membrane transport                                                          
    *Atp1a1*                                                     Na/K ATPase, α1   ATPase, Na^+^/K^+^ transporting, α1 polypeptide
    *Atp1a2*                                                     Na/K ATPase, α2   ATPase, Na^+^/K^+^ transporting, α2 polypeptide
    *Atp1a3*                                                     Na/K ATPase, α3   ATPase, Na^+^/K^+^ transporting, α3 polypeptide
    *Atp1b1*                                                     Na/K ATPase, β1   ATPase, Na^+^/K^+^ transporting, β1 polypeptide
    *Atp2b1*                                                     Na/K ATPase, β2   ATPase, Ca^++^ transporting, plasma membrane 1
    *Slc8a1*                                                     NCX1              Solute carrier family 8 (sodium/calcium exchanger), member 1
    *Trpc1*                                                      TRPC1             Transient receptor potential channel 1
    *Trpc3*                                                      TRPC3             Transient receptor potential channel 3
    *Trpc4*                                                      TRPC4             Transient receptor potential channel 4
    *Trpc6*                                                      TRPC6             Transient receptor potential channel 6
  Intracellular Ca^2+^ transport and Ca^2+^ regulation                             
    *Atp2a2*                                                     SERCA2            Sarcoplasmic/endoplasmic reticulum calcium ATPase 2
    *Calm1*                                                      Calm1             Calmodulin1
    *Calm3*                                                      Calm3             Calmodulin3
    *Casq2*                                                      Casq2             Calsequestrin 2
    *Itpr1*                                                      IP3R1             Inositol 1,4,5-trisphosphate receptor, type 1
    *Itpr2*                                                      IP3R2             Inositol 1,4,5-trisphosphate receptor, type 2
    *Itpr3*                                                      IP3R3             Inositol 1,4,5-trisphosphate receptor, type 3
    *Ryr2*                                                       RYR2              Ryanodine receptor 2
    *Ryr3*                                                       RYR3              Ryanodine receptor 3
    *Pln*                                                        PLB               Phospholamban
  Hyperpolarization-activated cyclic nucleotide-gated channels                     
    *Hcn1*                                                       HCN1              Hyperpolarization-activated cyclic nucleotide-gated channels 1
    *Hcn2*                                                       HCN2              Hyperpolarization-activated cyclic nucleotide-gated channels 2
    *Hcn3*                                                       HCN3              Hyperpolarization-activated cyclic nucleotide-gated channels 3
    *Hcn4*                                                       HCN4              Hyperpolarization-activated cyclic nucleotide-gated channels 4
  Calcium channels                                                                 
    *Cacna1c*                                                    Ca~v~1.2          Voltage-dependent, L type, α1C subunit
    *Cacna1d*                                                    Ca~v~1.3          Voltage-dependent, L type, α1D subunit
    *Cacna1g*                                                    Ca~v~3.1          Voltage-dependent, T type, α1G subunit
    *Cacna1h*                                                    Ca~v~3.2          Voltage-dependent, T type, α1H subunit
    *Cacna2d1*                                                   Ca~v~α2δ1         Voltage-dependent, α2/δ subunit 1
    *Cacna2d2*                                                   Ca~v~α2δ2         Voltage-dependent, α2/δ subunit 2
    *Cacna2d3*                                                   Ca~v~α2δ3         Voltage-dependent, α2/δ subunit 3
    *Cacnb1*                                                     Ca~v~β1           Voltage-dependent, β1 subunit
    *Cacnb2*                                                     Ca~v~β2           Voltage-dependent, β2 subunit
    *Cacnb3*                                                     Ca~v~β3           Voltage-dependent, β3 subunit
    *Cacng4*                                                     Ca~v~γ4           Voltage-dependent, γ subunit 4
    *Cacng7*                                                     Ca~v~γ7           Voltage-dependent, γ subunit 7
  Sodium channels                                                                  
    *Scn1a*                                                      Na~v~1.1          Voltage gated, type Iα subunit
    *Scn3a*                                                      Na~v~1.3          Voltage gated, type IIIα subunit
    *Scn4a*                                                      Na~v~1.4          Voltage gated, type IVα subunit
    *Scn5a*                                                      Na~v~1.5          Voltage gated, type V, α subunit
    *Scn7a*                                                      Na~v~2.1          Voltage gated, type VII, α subunit
    *Scn8a*                                                      Na~v~1.6          Voltage gated, type VIII, α subunit
    *Scn1b*                                                      Na~v~β1           Voltage gated, type I, β subunit
    *Scn2b*                                                      Na~v~β2           Voltage gated, type II, β subunit
    *Scn3b*                                                      Na~v~β3           Voltage gated, type III, β subunit
  Potassium channels                                                               
    *Kcna1*                                                      K~v~1.1           Voltage gated shaker related subfamily A, member 1
    *Kcna2*                                                      K~v~1.2           Voltage gated shaker related subfamily A, member 2
    *Kcna3*                                                      K~v~1.3           Voltage gated shaker related subfamily A, member 3
    *Kcna4*                                                      K~v~1.4           Voltage gated shaker related subfamily A, member 4
    *Kcna5*                                                      K~v~1.5           Voltage gated shaker related subfamily A, member 5
    *Kcna6*                                                      K~v~1.6           Voltage gated shaker related subfamily A, member 6
    *Kcnb1*                                                      K~v~2.1           Voltage gated shab related subfamily B, member 1
    *Kcnd1*                                                      K~v~4.1           Voltage gated shal related subfamily D, member 1
    *Kcnd2*                                                      K~v~4.2           Voltage gated shal related subfamily D, member 2
    *Kcnd3*                                                      K~v~4.3           Voltage gated shal related subfamily D, member 3
    *Kcnh2*                                                      ERG-1             Ether-a-go-go-related protein 1
    *Kcnip2*                                                     KChIP2            Kv channel interacting protein 2
    *Kcnn1*                                                      SK1               Ca^++^ activated intermediate/small conductance subfamily n α, member 1
    *Kcnn2*                                                      SK2               Ca^++^ activated intermediate/small conductance subfamily n α, member 2
    *Kcnn3*                                                      SK3               Ca^++^ activated intermediate/small conductance subfamily n α, member 3
    *Kcnq1*                                                      K~v~7.1           Voltage gated KQT-like subfamily Q, member 1
    *Kcnj2*                                                      K~ir~2.1          Inwardly rectifying subfamily J, member 2
    *Kcnj3*                                                      K~ir~3.1          Inwardly rectifying subfamily J, member 3
    *Kcnj5*                                                      K~ir~3.4          Inwardly rectifying subfamily J, member 5
    *Kcnj8*                                                      K~ir~6.1          Inwardly rectifying subfamily J, member 8
    *Kcnj11*                                                     K~ir~6.2          Inwardly rectifying subfamily J, member 11
    *Kcnj12*                                                     K~ir~2.2          Inwardly rectifying subfamily J, member 12
    *Kcnj14*                                                     K~ir~2.4          Inwardly rectifying subfamily J, member 14
    *Kcnk1*                                                      TWIK1             Two pore domain subfamily K, member 1
    *Kcnk2*                                                      TREK1             Two pore domain subfamily K, member 2
    *Kcnk3*                                                      K~2P~3.1          Two pore domain subfamily K, member 3
    *Kcnk5*                                                      K~2P~5.1          Two pore domain subfamily K, member 5
    *Kcnk6*                                                      TWIK2             Two pore domain subfamily K, member 6
  Miscellaneous proteins                                                           
    *Abcc8*                                                      SUR1              ATP-binding cassette transporter sub-family C member 8
    *Abcc9*                                                      SUR2              ATP-binding cassette, sub-family C member 9
    *Nppa*                                                       ANP               Atrial natriuretic peptide
    *Nppb*                                                       BNP               Brain natriuretic peptide
    *Pias3*                                                      KChAP             Protein inhibitor of activated STAT, 3

###### 

General characteristics of streptozotocin-induced diabetic rats.

  Characteristics                  Control       Streptozotocin
  -------------------------------- ------------- --------------------------------------------------------------
  Bodyweight (g)                   401.56±9.68   246.44±13.28^[a](#tfn2-mmr-16-04-3720){ref-type="table-fn"}^
  Heart weight (g)                   1.37±0.03   1.08±0.04^[a](#tfn2-mmr-16-04-3720){ref-type="table-fn"}^
  Heart weight/bodyweight (mg/g)     3.42±0.06   4.47±0.12^[a](#tfn2-mmr-16-04-3720){ref-type="table-fn"}^
  Blood glucose (mg/dl)            99.88±2.07    514.69±18.86^[a](#tfn2-mmr-16-04-3720){ref-type="table-fn"}^

Data are presented as the mean ± standard error of the mean, n=16 hearts,

P\<0.01.
